ANABV
AnaptysBio, Inc. Common Stock When IssuedKey Statistics
About AnaptysBio, Inc. Common Stock When Issued
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative antibody therapeutics aimed at severe diseases, particularly in the fields of immunology and oncology. Leveraging its proprietary platform, the company generates high-quality, diverse monoclonal antibodies to tackle significant unmet medical needs. AnaptysBio's robust pipeline includes promising therapeutic candidates currently in clinical trials, reflecting its commitment to advancing antibody-based therapies. Through strategic collaborations and a strong development framework, AnaptysBio is poised to deliver transformative treatment options that improve patient outcomes in critical disease areas.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | 0 |
| Float | $17.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting